ABL1 is an inclusion eligibility criterion in 8 clinical trials for marginal zone lymphoma, of which 3 are open and 5 are closed. Of the trials that contain ABL1 status and marginal zone lymphoma as inclusion criteria, 3 are phase 1 (2 open), 4 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

AFF1 is an inclusion eligibility criterion in 7 clinical trials for marginal zone lymphoma, of which 3 are open and 4 are closed. Of the trials that contain AFF1 status and marginal zone lymphoma as inclusion criteria, 3 are phase 1 (2 open), 3 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

BCL2 is an inclusion eligibility criterion in 7 clinical trials for marginal zone lymphoma, of which 5 are open and 2 are closed. Of the trials that contain BCL2 status and marginal zone lymphoma as inclusion criteria, 4 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2/phase 3 (1 open) [3].

BCL6 is an inclusion eligibility criterion in 6 clinical trials for marginal zone lymphoma, of which 5 are open and 1 is closed. Of the trials that contain BCL6 status and marginal zone lymphoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2/phase 3 (1 open) [3].

BCR is altered in 1.32% of marginal zone lymphoma patients [2].

BCR is an inclusion eligibility criterion in 8 clinical trials for marginal zone lymphoma, of which 3 are open and 5 are closed. Of the trials that contain BCR status and marginal zone lymphoma as inclusion criteria, 3 are phase 1 (2 open), 4 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

BIRC3 is altered in 4.23% of marginal zone lymphoma patients [2].

Chlorambucil and rituximab have evidence of efficacy in patients with BIRC3 mutation in marginal zone lymphoma [3].

BTK is an inclusion eligibility criterion in 1 clinical trial for marginal zone lymphoma, of which 0 are open and 1 is closed. Of the trial that contains BTK status and marginal zone lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

CBFB is an inclusion eligibility criterion in 1 clinical trial for marginal zone lymphoma, of which 0 are open and 1 is closed. Of the trial that contains CBFB status and marginal zone lymphoma as inclusion criteria, 1 is no phase specified (0 open) [3].

CCND1 is an inclusion eligibility criterion in 3 clinical trials for marginal zone lymphoma, of which 2 are open and 1 is closed. Of the trials that contain CCND1 status and marginal zone lymphoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

DEK is an inclusion eligibility criterion in 6 clinical trials for marginal zone lymphoma, of which 2 are open and 4 are closed. Of the trials that contain DEK status and marginal zone lymphoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [3].

ELL is an inclusion eligibility criterion in 6 clinical trials for marginal zone lymphoma, of which 2 are open and 4 are closed. Of the trials that contain ELL status and marginal zone lymphoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [3].

FLT3 is altered in 2.44% of marginal zone lymphoma patients [2].

FLT3 is an inclusion eligibility criterion in 8 clinical trials for marginal zone lymphoma, of which 3 are open and 5 are closed. Of the trials that contain FLT3 status and marginal zone lymphoma as inclusion criteria, 3 are phase 1 (2 open), 4 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

IGH is an inclusion eligibility criterion in 3 clinical trials for marginal zone lymphoma, of which 2 are open and 1 is closed. Of the trials that contain IGH status and marginal zone lymphoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

IKZF1 is an inclusion eligibility criterion in 3 clinical trials for marginal zone lymphoma, of which 1 is open and 2 are closed. Of the trials that contain IKZF1 status and marginal zone lymphoma as inclusion criteria, 3 are phase 2 (1 open) [3].

KIT is an inclusion eligibility criterion in 2 clinical trials for marginal zone lymphoma, of which 1 is open and 1 is closed. Of the trials that contain KIT status and marginal zone lymphoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is no phase specified (0 open) [3].

KMT2A is altered in 3.66% of marginal zone lymphoma patients [2].

KMT2A is an inclusion eligibility criterion in 7 clinical trials for marginal zone lymphoma, of which 3 are open and 4 are closed. Of the trials that contain KMT2A status and marginal zone lymphoma as inclusion criteria, 3 are phase 1 (2 open), 3 are phase 2 (1 open), and 1 is no phase specified (0 open) [3].

MALT1 is altered in 1.45% of marginal zone lymphoma patients [2].

Chlorambucil and rituximab have evidence of efficacy in patients with MALT1 mutation in marginal zone lymphoma [3].

MECOM is an inclusion eligibility criterion in 9 clinical trials for marginal zone lymphoma, of which 5 are open and 4 are closed. Of the trials that contain MECOM status and marginal zone lymphoma as inclusion criteria, 3 are phase 1 (2 open), 5 are phase 2 (3 open), and 1 is no phase specified (0 open) [3].

MLF1 is an inclusion eligibility criterion in 5 clinical trials for marginal zone lymphoma, of which 3 are open and 2 are closed. Of the trials that contain MLF1 status and marginal zone lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 4 are phase 2 (3 open) [3].

MLLT1 is an inclusion eligibility criterion in 6 clinical trials for marginal zone lymphoma, of which 2 are open and 4 are closed. Of the trials that contain MLLT1 status and marginal zone lymphoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [3].

MLLT10 is an inclusion eligibility criterion in 6 clinical trials for marginal zone lymphoma, of which 2 are open and 4 are closed. Of the trials that contain MLLT10 status and marginal zone lymphoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [3].

MLLT3 is an inclusion eligibility criterion in 6 clinical trials for marginal zone lymphoma, of which 2 are open and 4 are closed. Of the trials that contain MLLT3 status and marginal zone lymphoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [3].

MLLT4 is an inclusion eligibility criterion in 6 clinical trials for marginal zone lymphoma, of which 2 are open and 4 are closed. Of the trials that contain MLLT4 status and marginal zone lymphoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [3].

MYC is an inclusion eligibility criterion in 8 clinical trials for marginal zone lymphoma, of which 6 are open and 2 are closed. Of the trials that contain MYC status and marginal zone lymphoma as inclusion criteria, 4 are phase 1 (2 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2/phase 3 (1 open) [3].

MYH11 is an inclusion eligibility criterion in 1 clinical trial for marginal zone lymphoma, of which 0 are open and 1 is closed. Of the trial that contains MYH11 status and marginal zone lymphoma as inclusion criteria, 1 is no phase specified (0 open) [3].

NPM1 is an inclusion eligibility criterion in 5 clinical trials for marginal zone lymphoma, of which 3 are open and 2 are closed. Of the trials that contain NPM1 status and marginal zone lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 4 are phase 2 (3 open) [3].

NRIP3 is an inclusion eligibility criterion in 6 clinical trials for marginal zone lymphoma, of which 2 are open and 4 are closed. Of the trials that contain NRIP3 status and marginal zone lymphoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [3].

NUP214 is an inclusion eligibility criterion in 6 clinical trials for marginal zone lymphoma, of which 2 are open and 4 are closed. Of the trials that contain NUP214 status and marginal zone lymphoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [3].

PBX1 is an inclusion eligibility criterion in 6 clinical trials for marginal zone lymphoma, of which 3 are open and 3 are closed. Of the trials that contain PBX1 status and marginal zone lymphoma as inclusion criteria, 3 are phase 1 (2 open) and 3 are phase 2 (1 open) [3].

PLCG2 is altered in 1.61% of marginal zone lymphoma patients [2].

PLCG2 is an inclusion eligibility criterion in 1 clinical trial for marginal zone lymphoma, of which 0 are open and 1 is closed. Of the trial that contains PLCG2 status and marginal zone lymphoma as inclusion criteria, 1 is phase 1 (0 open) [3].

RPN1 is an inclusion eligibility criterion in 9 clinical trials for marginal zone lymphoma, of which 5 are open and 4 are closed. Of the trials that contain RPN1 status and marginal zone lymphoma as inclusion criteria, 3 are phase 1 (2 open), 5 are phase 2 (3 open), and 1 is no phase specified (0 open) [3].

RUNX1 is an inclusion eligibility criterion in 1 clinical trial for marginal zone lymphoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1 status and marginal zone lymphoma as inclusion criteria, 1 is no phase specified (0 open) [3].

RUNX1T1 is altered in 2.7% of marginal zone lymphoma patients [2].

RUNX1T1 is an inclusion eligibility criterion in 1 clinical trial for marginal zone lymphoma, of which 0 are open and 1 is closed. Of the trial that contains RUNX1T1 status and marginal zone lymphoma as inclusion criteria, 1 is no phase specified (0 open) [3].

TCF3 is altered in 3.57% of marginal zone lymphoma patients [2].

TCF3 is an inclusion eligibility criterion in 6 clinical trials for marginal zone lymphoma, of which 3 are open and 3 are closed. Of the trials that contain TCF3 status and marginal zone lymphoma as inclusion criteria, 3 are phase 1 (2 open) and 3 are phase 2 (1 open) [3].

TP53 is altered in 4.88% of marginal zone lymphoma patients [2].

TP53 is an inclusion eligibility criterion in 6 clinical trials for marginal zone lymphoma, of which 2 are open and 4 are closed. Of the trials that contain TP53 status and marginal zone lymphoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 2 (0 open), and 1 is no phase specified (0 open) [3].